IP Library Granted Patent US 9,820,935
Granted Patent B2
US 9,820,935 · App. 15/066,689 · Granted Nov 21, 2017

Delivery of corticosteroids through iontophoresis

Inventors: Mike Jaffe (East Hartford, CT); Gary Cook (Westford, CT); Perry Calias (Melrose, MA); Michael A. Patane (Waltham, MA)
Assignee: EyeGate Pharmaceuticals, Inc.
A61K9/0048A61F9/0008A61K9/0009A61K31/573A61K41/00A61N1/0448A61N1/303A61N1/044
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,820,935
App. No.
15/066,689
Granted
Nov 21, 2017
Kind
B2
Abstract

Disclosed herein are formulations of dexamethasone or a prodrug thereof suitable for delivery by ocular iontophoresis and methods of use thereof.

Claims (11)

1. A method for iontophoretically delivering dexamethasone phosphate into the eye of a subject in need of such treatment, comprising:

a) administering a formulation of dexamethasone phosphate to the eye of the subject; wherein the formulation comprises:

i) 25 mg/mL to 40 mg/mL of a dexamethasone phosphate solution; and

ii) wherein the pH of the formulation has been adjusted to between 5.7 and 6.1 with a buffering agent; and

b) performing ocular iontophoresis to the eye of the subject.

2. The method of claim 1 , wherein the subject is being treated for an ophthalmic condition selected from uveitis, dry eye, post-operative inflammation, diabetic macula edema and corneal graft rejection.

3. The method of claim 1 , wherein the subject is being treated for an inflammatory ophthalmic condition.

4. The method of claim 1 , wherein the subject is being treated for uveitis.

5. The method of claim 1 , wherein the subject is being treated for anterior segment uveitis or dry eye.

6. The method of claim 1 , wherein the step of ocular iontophoresis is carried out prior to, during or after the step of administering the dexamethasone phosphate.

7. The method of claim 1 , wherein the dexamethasone phosphate is delivered by an iontophoretic dose of about 0.5 mAmin to about 50 mAmin.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 19, 2017
From: JAFFE, MIKE; COOK, GARY; CALIAS, PERRY; PATANE, MICHAEL A.
To: EYEGATE PHARMACEUTICALS, INC.
Reel/Frame 042055/0910 →
Continuity (5)
Continuation 13469481 · May 11, 2012
Division 12391836 · Feb 24, 2009
Provisional Application 61047950 · Apr 25, 2008
Provisional Application 61031267 · Feb 25, 2008
Related Publication 20160263024A1 · Sep 15, 2016